ABT Stock Recent News

Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segments offsets weakness in Diagnostics and China sales, showcasing resilience and adaptability. Management's focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policies like dividend increases support long-term value.

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With Abbott acquiring rights to 4 more biosimilar products and a double-digit CAGR in the target biosimilar emerging markets, the EPD business could stimulate EPS growth beyond Medical Devices. With an excellent balance sheet and over 50 consecutive years of dividend increases, Abbott is a robust long-term investment for income investors.

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising payouts in 2025 and an average growth rate of 4.86%. I identified 21 Aristocrats as both potentially undervalued and offering a projected long-term annualized return of at least 10%.

I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs.

In the closing of the recent trading day, Abbott (ABT) stood at $133.67, denoting a -2.71% move from the preceding trading day.

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.

The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's passive income stream and never have to work another day in their life.

ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.

Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a collective 2025 growth rate of 5.19%, despite some downward earnings revisions. Seventeen Dividend Kings appear undervalued and offer long-term annualized expected returns of at least 10%, based on Dividend Yield Theory analysis.